Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
World Preview 2023: Pharma's Age of Uncertainty
The pharmaceutical sector is entering new and unfamiliar territory. Key assumptions, such as the unrivalled profitability of the US market and the reliance on large M&A to spur growth, are getting a serious shake-up. From the FDA's shifting temperament and the ripple effects of the IRA, commercial disruptions, dealmaking ambiguities and…
Report library
JP Morgan Healthcare Conference 2023
The JP Morgan Healthcare Conference 2023 was the first in-person iteration of the event since 2020. After a rather lacklustre 2022 conference, this year’s event started…
Evaluate Vantage 2023 Preview Infographic
The new year is upon us! What should biopharma companies and investors expect from 2023? Can they hope for better than 2022 or will it be more of the same? We already…
ASH 2022
As the final big conference of the year, ASH is always something a harbinger of things to come. This year was no exception with plenty to keep pharma-watchers pondering…
The Billion Dollar Question: Are payer perspectives part of your strategy?
There are many factors that impact the success of a new therapy. Efficacy, differentiation, market size, and of course, cost. For this last point, the importance of…
Evaluate Vantage 2023 Preview
After a tough year for many in biopharma, what’s the outlook for 2023? Evaluate Vantage’s preview sets out the projects waiting in the wings that could drive some…
ASH 2022 Preview
The 2022 ASH Annual Meeting is due to take place on December 10-13 in New Orleans, Louisiana. Get yourself prepared with Evaluate Vantage's preview of the…
How to spot blockbuster potential?
In 2021, the pharma industry invested over $600 billion in R&D, M&A and licensing in search of the next life-changing and market-leading products. With a patent…
Pharma Market Drivers Part Three: Blowin’ in the wind
There are some things in life you want to be consistent and predictable. Interest rates. Train timetables. The weather. And if you work in the pharma industry, the…
Q3 Round Up: Alive but not kicking report
What happened in Q3? Did the glimmers of light we saw at the start of the quarter really come to anything or were they a false dawn? In this eBook, we investigate whether…
Q3 Round up: Alive but not kicking infographic
In this quarterly snapshot, we highlight financial and business trends in biopharma. Download our Q3 Roundup infographic now for our quick take on M&A activity, the…